Paris, France, Boston, United States, 7 June 2022 – L’Institut Servier, Gustave Roussy (Villejuif, France), and Dana-Farber Cancer Institute (Boston, USA) have signed a cooperation agreement to foster exchange and develop bilateral collaboration among researchers from these two renowned oncology centers.

Read more about Dana-Farber Cancer Institute, Gustave Roussy, and L’Institut Servier sign an oncology cooperation agreement

ASCO 2022 - The SACHA study supports the use of innovative anticancer therapies in children outside clinical trials

back to job offer list

back to clinical trials

ASCO 2022

The SACHA study supports the use of innovative anticancer therapies in children outside clinical trials

Villejuif, 7 june 2022

ASCO 2022 - RAGNAR study: the benefits of targeted therapy beyond bladder cancer

back to job offer list

back to clinical trials

ASCO 2022

ASCO 2022

back to job offer list

back to clinical trials

ASCO 2022 -A promising targeted therapy for treatment of relapses of acute myeloid leukaemia

back to job offer list

back to clinical trials

ASCO 2022

05/18/2022

PEACE-1 : l’étude qui défie les cancers de la prostate métastatique

Grâce à une combinaison de 3 médicaments, dont une hormonothérapie de nouvelle génération, les patients atteints de cancers de la prostate métastatique gagnent deux ans et demi sans rechute de la maladie et voient leur mortalité réduite de 25 %. C’est ce qu’a démontré PEACE-1 (Prostate Cancer Consortium in Europe), une grande étude européenne...

L'essentiel de l'ASCO 2022, par Gustave Roussy

Lucie Albert, infirmière au service des Urgences (Rouergue)

Dana-Farber Cancer Institute, Gustave Roussy, and L’Institut Servier sign an oncology cooperation agreement

The SACHA study supports the use of innovative anticancer therapies in children outside clinical trials

PEACE-1 : l’étude qui défie les cancers de la prostate métastatique

Pages